The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MM-10-001 in advanced non-small cell lung cancer.
M. C. Cristea
No relevant relationships to disclose
M. Koczywas
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
Research Funding - CanBas; GlycaNova; Lilly; Synta
K. L. Reckamp
Consultant or Advisory Role - Amgen; Tragara Pharmaceuticals
Honoraria - Genentech; Lilly
Research Funding - Agennix; Amgen; OSI Pharmaceuticals; Pfizer
S. F. Lacey
No relevant relationships to disclose
A. Rotter
No relevant relationships to disclose
P. H. Frankel
No relevant relationships to disclose
S. Fouladi Rad
No relevant relationships to disclose
X. Liu
No relevant relationships to disclose
V. Tran
No relevant relationships to disclose
E. Reorizo
No relevant relationships to disclose
M. Kalos
No relevant relationships to disclose